Stratified Medicine to Optimise the Treatment of Patients with Hepatitis C Virus Infection

  • no-js


STOP-HCV is a Medical Research Council (MRC) funded consortium which aims to use patient information to establish the most effective and cost effective treatments for patients with Hepatitis C Virus.


STOP-HCV Partners

The STOP-HCV consortium is formed of 21 partners representing academia, industry and the Hepatitis C Trust.

See partners >>

Latest News

Gilead Sciences BOSON trial - clinical findings will be presented by Professor Graham Foster at the annual European Association for the Study of Liver Disease meeting in Vienna, 22-26 April 2015. 

'HCV Research Consortia: A 10,000 UK patient cohort delibvering translational research' - STOP-HCV will be presenting at this BVHG Showcase Event in Manchester on 5 June 2015

Older news

Gilead Sciences BOSON trial - the Clinical Research Network's 'Spotlight on hepatitis research' highlights the importance of the academic-industrial collaboration within STOP-HCV.

28th July 2014 was World Hepatitis Day. To mark the occasion, efforts undertaken by STOP-HCV researchers to map the global distribution & prevalance of hepatitis C were published in Hepatology.

STOP-HCV award now active

The official start date for STOP-HCV was 16th September 2013. Work has now begun to meet the consortiums aims.